ライフサイエンスコーパス: substance-related disorder

1 -, opioid-, sedative-, stimulant-, and other substance-related disorders).

2 medication for nicotine dependence and other substance-related disorders.

3 d Hispanics (21.0%) had the highest rates of substance-related disorders.

4 ined treatment for other comorbid mental and substance-related disorders.

5 fic negative course marked by antisocial and substance-related disorders.

6 well as schizophrenia, bipolar disorder, and substance-related disorders.

7 sorders to the chapter formerly reserved for substance-related disorders.

8 oups also are disproportionately affected by substance-related disorders.

9 population in the United States, data about substance-related disorders among adolescents of various

10 t substance users indicated elevated odds of substance-related disorders among Native Americans, adol

11 f 642 patients were assessed, of whom 39 had substance-related disorder and dysthymia and 308 had sub

12 Patients with substance-related disorder and dysthymia are referred to

13 Patients with substance-related disorder and dysthymia had received mo

14 Patients with substance-related disorder and dysthymia used 4.7 times

15 vious treatment among patients with comorbid substance-related disorder and dysthymia, as compared to

16 s several times higher for the patients with substance-related disorder and dysthymia.

17 epression, anxiety, stress-related disorder, substance-related disorder, and ADHD, and for use of ant

18 phrenia or psychosis, personality disorders, substance-related disorders, and self-harm.

19 ncreased co-occurring anxiety-, stress-, and substance-related disorders, and they used this informat

20 od disorders (IRR, 0.84; 95% CI, 0.83-0.86), substance-related disorders (IRR, 0.83; 95% CI, 0.81-0.8

21 e-related disorder and dysthymia and 308 had substance-related disorder only (the remaining patients

22 rder treatment more often than patients with substance-related disorder only but are referred to (or

23 isorder treatment dollars than patients with substance-related disorder only, although their demograp

24 c treatment no more often than patients with substance-related disorder only.

25 and dysthymia, as compared to patients with substance-related disorder only.

26 dentified several highly comorbid disorders (substance-related disorders, personality disorders, depr

27 ofit: 18.8%, proprietary: 12.6%), a comorbid substance-related disorder (public: 29.9%, nonprofit: 31

28 order (including common mental disorders and substance-related disorders), suicide-related behaviors,

29 Although substance-related disorder treatment differed considerab

30 d disorder and dysthymia used 4.7 times more substance-related disorder treatment dollars than patien

31 ted disorder and dysthymia had received more substance-related disorder treatment in 18 of 20 measure

32 rder and dysthymia are referred to (or seek) substance-related disorder treatment more often than pat

33 The cost of previous substance-related disorder treatment was several times h

34 Substance-related disorders were assessed by standardize

35 e more likely in psychosis spectrum 22q11DS; substance-related disorders were more likely in ND.

36 rved for parental diagnoses of psychosis and substance-related disorders, which more strongly predict

37 disproportionately preceded chronic pain and substance-related disorders, while asthma disproportiona

38 gs in the past year; 7.9% met criteria for a substance-related disorder, with Native Americans having

39 The DSM-5 Substance-Related Disorders Work Group considered these